MCE products for research use only. We do not sell to patients.

18β-Glycyrrhetinic acid

MCE China：18β-Glycyrrhetinic acid

Brand：MedChemExpress (MCE)

Cat. No.HY-N0180

CAS：471-53-4

Purity：99.88%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months

Shipping：Room temperature in continental US; may vary elsewhere.

Description：18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhiza uralensis and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties.

In Vitro：18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhizae Radix and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties. MTS assay demonstrates that 24 h treatment of 18β-Glycyrrhetinic acid suppresses cell proliferation in both cell lines in a dose-dependent manner. 18β-Glycyrrhetinic acid at 160 μM significantly decreases the percentage of viable cells to around 40.5±10.5% in A549 and 38.3±4.6% in NCI-H460 (pPARP and increases the levels of cleaved-PARP[1].

In Vivo：Rats in 18β-Glycyrrhetinic acid+Triptolide (TP) group which receive low-dose 18β-Glycyrrhetinic acid (50 mg/kg) have significant reductions in the three serum parameters when compare with TP rats. Rats in 18β-Glycyrrhetinic acid+TP group which receive the high-dose 18β-Glycyrrhetinic acid (100 mg/kg) have slightly lowered the levels of three liver enzymes, the reductions do not reach statistical significance compare with TP group. Contrastingly, preadministration of low-dose 18β-Glycyrrhetinic acid protects animals from TP-induced hepatic lesions. On the contrary, low-dose 18β-Glycyrrhetinic acid (50 mg/kg) markedly suppresses the release of the four cytokines above[3].

Animal Administration：Healthy Wistar rats (male, 200±20 g) are used and divided into five groups with 10 individuals for each group randomly. Animals in normal control (NC) group receive distilled water for 6 days and 0.5% CMC-Na for the last 3 days. Rats in Triptolide model group (TP), 18β-Glycyrrhetinic acid low-dose group (GAL+TP), and 18β-Glycyrrhetinic acid high-dose group (GAH+TP) receive distilled water, 18β-Glycyrrhetinic acid (50 mg/kg, p.o., dissolved in distilled water), or 18β-Glycyrrhetinic acid (100 mg/kg, p.o., dissolved in distilled water) for consecutive 6 days, respectively, and liver injury is induced by TP (2.4 mg/kg, p.o., suspended in 0.5% CMC-Na) for the last 3 days. Animals in the above three groups receive TP 6 hours after distilled water or 18β-Glycyrrhetinic acid treatment on the last 3 days[3].

Cell Assay：Primary microglia cultures are used in this study. For treatment assay, microglia are incubated with complete DMEM and stimulated with or without 100 ng/mL IFN-γ in the presence or absence of 18β-Glycyrrhetinic acid (25 μM and 50 μM) at 37°C in a humidified incubator with 5% CO2. For cell migration assay, the isolated primary microglia that seeded in complete DMEM medium are stimulated with or without IFN-γ (100 ng/mL), and treated with different doses of 18β-Glycyrrhetinic acid, 24 h later, the microglia culture supernatants are collected and added to the lower chambers of Transwell inserts[2].

Hot selling product：Phenytoin  | Gramicidin A  | SLF  | N,N-Dimethylsphingosine  | Ascomycin  | Sulfo-NHS-Biotin (sodium)  | Gamma glutamyltransferase  | STAD 2  | Ginsenoside Ro  | Aureothricin

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Huang RY, et al. 18β-Glycyrrhetinic acid suppresses cell proliferation through inhibiting thromboxane synthase in non-small cell lung cancer. PLoS One. 2014 Apr 2;9(4):e93690.  [Content Brief]

[2]. Zhou J, et al. 18β-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination. Sci Rep. 2015 Sep 2;5:13713.  [Content Brief]

[3]. Yang G, et al. Protective Effect of 18β-Glycyrrhetinic Acid against Triptolide-Induced Hepatotoxicity in Rats. Evid Based Complement Alternat Med. 2017;2017:3470320.  [Content Brief]